Segment Information

We determined our reportable segments under the provisions of U.S. GAAP related to disclosures about segments of an enterprise. Management has concluded that Mobile Solutions, Power Solutions, and Life Sciences each constitutes an operating segment as each engages in business activities for which it earns revenues and incurs expenses for which separate financial information is available, and this is the level at which the Chief Operating Decision Maker (“CODM”) reviews discrete financial information for purposes of allocating resources and assessing performance. In making this determination, management considered the form and content of the financial information that is regularly reviewed by the CODM. As described in Note 1, in January 2018, we implemented a new enterprise and management structure and reorganized our businesses into the Mobile Solutions, Power Solutions and Life Sciences groups based principally on the end markets they serve. In the first quarter of 2018, we began reporting our financial results based on these new reportable segments. Prior year amounts have been restated to conform to the current year presentation.

Mobile Solutions

Mobile Solutions is focused on growth in the general industrial and automotive end markets. We have developed an expertise in manufacturing highly complex, system critical components for fuel systems, engines and transmissions, power steering systems and electromechanical motors on a high-volume basis. This expertise has been gained through investment in technical capabilities, processes and systems, and skilled program management and product launch capabilities.

Power Solutions

Power Solutions is focused on growth in the electrical, and aerospace and defense end markets. Within this group we combine materials science expertise with advanced engineering and production capabilities to design and manufacture a broad range of high-precision metal and plastic components, assemblies and finished devices used in applications ranging from power control to flight control and for military devices.

We manufacture a variety of products including electrical contacts, connectors, contact assemblies and precision stampings for the electrical end market and high precision products for the aerospace and defense end markets utilizing our extensive process technologies for optical grade plastics, thermally conductive plastics, titanium, Inconel, magnesium and electroplating.

Life Sciences

Life Sciences is focused on growth in the medical end market. Within this group we combine advanced engineering and production capabilities to design and manufacture a broad range of high-precision metal and plastic components, assemblies and finished devices.

We manufacture a variety of components, assemblies and instruments, such as surgical knives, bioresorbable implants, surgical staples, cases and trays, orthopedic implants and tools, laparoscopic devices, and drug delivery devices for the medical and life sciences end market.

Segment Results

The following table presents results of continuing operations for each reportable segment.



	Mobile Solutions		Power Solutions		Life Sciences		Corporate and Consolidations				Total Continuing Operations
Three Months Ended September 30, 2018
Net sales	$	81,805	$	46,082	$	78,363	$	(567	)	(a)	$	205,683
Income (loss) from operations	$	4,657	$	2,706	$	6,717	$	(8,199	)		$	5,881
Interest expense											(18,608		)
Other											(6,932		)
Loss from continuing operations before benefit for income taxes and share of net income from joint venture											$	(19,659	)

Nine Months Ended September 30, 2018
Net sales	$	259,678	$	144,584	$	168,716	$	(1,798	)	(a)	$	571,180
Income (loss) from operations	$	21,822	$	13,939	$	12,962	$	(39,440	)		$	9,283
Interest expense											(46,592		)
Other											(21,444		)
Loss from continuing operations before benefit for income taxes and share of net income from joint venture											$	(58,753	)

Three Months Ended September 30, 2017
Net sales	$	81,664	$	44,824	$	22,154	$	(486	)	(a)	$	148,156
Income (loss) from operations	$	6,799	$	4,166	$	3,011	$	(8,425	)		$	5,551
Interest expense											(12,739		)
Other											782
Loss from continuing operations before benefit for income taxes and share of net income from joint venture											$	(6,406	)

Nine Months Ended September 30, 2017
Net sales	$	254,768	$	141,982	$	68,397	$	(1,489	)	(a)	$	463,658
Income (loss) from operations	$	28,088	$	17,780	$	10,431	$	(24,254	)		$	32,045
Interest expense											(39,916		)
Other											(38,433		)
Loss from continuing operations before benefit for income taxes and share of net income from joint venture											$	(46,304	)


(a)	Includes eliminations of intersegment transactions occurring during the ordinary course of business.



	Total Assets as of
	September 30, 2018		December 31, 2017
Mobile Solutions	$	446,830	$	428,321
Power Solutions	404,701		383,063
Life Sciences	806,828		355,703
Corporate and Consolidations	104,963		307,916
Total	$	1,763,322	$	1,475,003

The Paragon Medical business acquired on May 7, 2018, contributed $70.0 million to net sales and $2.2 million to income from operations in the Life Sciences group after the acquisition date through September 30, 2018. Other businesses acquired in 2018 contributed $7.3 million to net sales and $0.2 million to income from operations in the Life Sciences and Power Solutions groups after each acquisition date through September 30, 2018.